1. Introduction {#sec1-molecules-23-00310}
===============

Cancer is the most threatening and difficult-to-treat disease. Traditional Chinese herbal medicines have been applied for the treatment of cancers for many years \[[@B1-molecules-23-00310]\]. Compounds isolated from traditional Chinese herbs exhibit pharmacological activities \[[@B2-molecules-23-00310]\] and have been recognized as valuable resources for the development of novel anti-cancer drugs \[[@B3-molecules-23-00310]\]. Scutellarin (**1**, [Figure 1](#molecules-23-00310-f001){ref-type="fig"}) is the major active flavonoid extracted from the traditional Chinese herbal medicine Erigeron breviscapus (Vant.) Hand-Mazz., which is used clinically in cardiovascular diseases \[[@B4-molecules-23-00310]\]. Recently, accumulating evidence has highlighted the potential role of scutellarin and its main metabolite scutellarein (**2**, [Figure 1](#molecules-23-00310-f001){ref-type="fig"}) \[[@B5-molecules-23-00310]\] in the treatment of cancer \[[@B6-molecules-23-00310],[@B7-molecules-23-00310],[@B8-molecules-23-00310]\]. Nevertheless, low stability and poor lipophilicity of scutellarin and scutellarein limited their further application \[[@B9-molecules-23-00310]\]. Derivatives have been synthesized to overcome these disadvantages and increase biological activity \[[@B10-molecules-23-00310],[@B11-molecules-23-00310],[@B12-molecules-23-00310]\]. We report herein the synthesis of a series of scutellarein derivatives with a long aliphatic chain and their evaluation as anti-cancer agents.

2. Results and Discussion {#sec2-molecules-23-00310}
=========================

The methodologies for preparing the target scutellarein derivatives are outlined in [Scheme 1](#molecules-23-00310-sch001){ref-type="scheme"}. Scutellarin (**1**) was reacted with acetic anhydride and catalytic 4-*N*,*N*-dimethylaminopyridine (DMAP) in pyridine under reflux to afford 5,6,7,4′-*O*-tetraacetyl scutellarein (**3**) in 54% yield and 6,7,4′-*O*-triacetyl scutellarein (**4**) in 23% yield. 6,7,4′-*O*-triacetyl scutellarein (**4**) is assigned its structure based on ^1^H-NMR analysis. Following literature protocols \[[@B13-molecules-23-00310],[@B14-molecules-23-00310]\], the assignment of the single free phenol hydroxyl group utilized the narrow peak shape and high chemical shift (12.90 ppm, CDCl~3~) of the hydroxyl proton. The single free phenol hydroxyl group is at the C-5 position, and can form a hydrogen bond with the carbonyl group at C-4 position \[[@B15-molecules-23-00310]\].

**3** and **4** are converted to 7-*O*-aliphatic-5,6,4′-*O*-triacetylscutellarein (**5**) and 7-*O*-aliphatic-6,4′-*O*-diacetylscutellarein (**6**) by reacting with RBr using K~2~CO~3~ in *N*,*N*-dimethylformamide (DMF). The position of aliphatic chain connected with scutellarein was clarified by using Hetero-nuclear Multiple-Bond Connectivity (HMBC). The triplet at 4.08 ppm in the spectrum of **5d** ([Figure 2](#molecules-23-00310-f002){ref-type="fig"}) belongs to the OCH~2~ protons of the aliphatic chain. A cross peak is observed at 155.68 ppm, and belongs to C-7. Similarly, the triplet at 4.06 ppm in the spectrum of **6a** ([Figure 3](#molecules-23-00310-f003){ref-type="fig"}) belongs to the OCH~2~ protons of the aliphatic chain. A cross peak is observed at 157.30 ppm, and belongs to C-7. The OCH~2~ protons of the aliphatic chain were correlated with C-7 as shown in [Figure 4](#molecules-23-00310-f004){ref-type="fig"} indicated that the aliphatic chain is bonded to the C-7 position \[[@B16-molecules-23-00310]\].

The biological activities of 7-*O*-aliphatic scutellarein derivatives **5a**--**d** and **6a**--**d** in inhibiting cancer cell line proliferation were assayed in vitro using CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay (MTS) according to the previously reported method \[[@B17-molecules-23-00310]\]. Anticancer drug sodium arsenite (NaAsO~2~) \[[@B18-molecules-23-00310],[@B19-molecules-23-00310]\] was used as a positive control. Unexpectedly, most of the compounds were not able to inhibit the cancer cell proliferation at concentrations ≤100 μM, as shown in [Table 1](#molecules-23-00310-t001){ref-type="table"}. However, the compounds **5a**, **5b**, **6a** and **6b** displayed anti-proliferation activity at concentrations ≤100 μM, and their activities were higher than both scutellarin and scutellarein. In particular, **6a** even showed stronger antiproliferative effects than the positive control NaAsO~2~ on Jurkat and HCT-116 cell lines. The results showed that the aliphatic chain enhanced the anti-proliferation activity. However, the anti-proliferation activity is not stronger when the aliphatic chain is longer. A proper long aliphatic chain is beneficial to enhancing the anti-proliferative activity of scutellarein. **6a** exhibited the strongest antiproliferative effects on Jurkat (IC~50~ = 1.80 μM), HCT-116 (IC~50~ = 11.50 μM) and MDA-MB-231 (IC~50~ = 53.91 μM). In addition, **6b** with a free phenol hydroxyl group at C-5 position exhibited stronger anti-proliferative effects than **5b**. These results indicate that the hydroxyl group at C-5 of scutellarein derivatives may be important anti-proliferative activity.

3. Materials and Methods {#sec3-molecules-23-00310}
========================

Reagents and solvents were obtained from commercial suppliers and used without further purification unless stated otherwise. Pyridine was dried by boiling with CaH~2~ prior to distillation and stored over KOH, DMF (*N*,*N*-dimethylformamide) was stored over 4 Å molecular sieves. Reactions were monitored by thin-layer chromatography (TLC), and performed on 0.2 mm silica gel GF254 plates using UV light as the visualizing agent. Chromatographic purification of products was accomplished using forced-flow chromatography on 300--400 mesh silica gel. The ^1^H-NMR (400 MHz, CDCl~3~) and ^13^C-NMR (100 MHz, CDCl~3~) spectra were measured on a Bruker AV 400 MHz (Bruker, Karlsruhe, Germany) in CDCl~3~ as solvent, using (TMS) as an internal standard, and chemical shifts are expressed as δ ppm.

*5,6,7,4′-O-Tetraacetyl scutellarein* (**3**) and *6,7,4′-O-triacetyl scutellarein* (**4**) Scutellarin (10 g, 21.6 mmol) was dissolved into the Ac~2~O/Pyridine(50 mL, 3:2, *v*/*v*) solution and reacted reflux for 4 h. After the reaction was completed (monitored by TLC), the solvent was removed, and the resulting residue was then purified by column chromatography on silica gel using 50% ethyl acetate in petroleum ether as eluent to afford **3** (5.3 g, 11.7 mmol, 54%) and **4** (2.1 g, 5.1 mmol, 23%).

*5,6,7,4′-O-Tetraacetyl scutellarein* (**3**) yellow solid. ^1^H-NMR (CDCl~3~, 400 MHz) δ: 7.88 (d, 2H, *J* = 8.4 Hz, Ar′-H-2,6), 7.49 (s, 1H, Ar-H-8), 7.27 (d, 2H, *J* = 6.0 Hz, Ar′-H-3,5); 6.62 (s, 1H, Ar-H-3); 2.44 (s, 3H, COCH~3~), 2.35 (s, 9H, COCH~3~ × 3).

*6,7,4′-O-Triacetyl scutellarein* (**4**) yellow solid, m.p. 261--264 °C. ^1^H-NMR (CDCl~3~, 400 MHz) δ: 12.90 (s, 1H, OH), 7.91 (d, 2H, *J* = 7.8 Hz, Ar′-H-2,6), 7.29 (d, 2H, *J* = 7.9 Hz, 2H, Ar′-H-3,5), 6.96 (s, 1H, Ar-H-3), 6.70 (s, 1H, Ar-H-8), 2.37 (s, 3H, COCH~3~), 2.35 (s, 6H, COCH~3~ × 2).

General Procedure for Preparation of 7-*O*-aliphatic-5,6,4′-*O*-triacetyl scutellarein (5) and 7-*O*-aliphatic-6,4′-*O*-diacetyl scutellarein (6).

To a solution of compound **3** or **4** (1 mmol) in anhydrous DMF (10 mL) was added K~2~CO~3~ (691 mg, 5 mmol) and RX (1.5 mmol), then the reaction mixture was stirred overnight at room temperature. The mixture was poured into water (50 mL), and then extracted with ethyl acetate (50 mL × 3), the organic layer was washed with brine (100 mL), dried over Na~2~SO~4~, filtered and concentrated under reduced pressure. The crude material that appeared was then purified by column chromatography on silica gel using 20% ethyl acetate in petroleum ether as eluent to afford **5** or **6**.

*7-O-Hexyl-5,6,4′-O-triacetylscutellarein* (**5a**); yellow solid; yield 72%; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.87 (d, *J* = 8.8 Hz, 2H, Ar′-H-2,6), 7.26 (d, *J* = 8.8 Hz, 2H, Ar′-H-3,5), 6.92 (s, 1H, Ar-H-3), 6.57 (s, 1H, Ar-H-8), 4.09 (t, *J* = 6.5 Hz, 2H, OCH~2~), 2.44 (s, 3H, COCH~3~), 2.34 (s, 3H, COCH~3~), 2.33 (s, 3H, COCH~3~), 1.88--1.76 (m, 2H, CH~2~), 1.49--1.42 (m, 2H, CH~2~), 1.39--1.31 (m, 4H, CH~2~ × 2), 0.92 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 176.23, 168.90, 168.73, 167.83, 161.23, 155.79, 155.69, 153.17, 141.77, 130.86, 128.94, 127.47, 122.32, 111.09, 108.26, 98.70, 69.63, 31.36, 28.69, 25.44, 22.52, 21.12, 20.85, 20.10, 13.94.

*7-O-Dodecyl-5,6,4′-O-triacetylscutellarein* (**5b**) yellow solid; yield 72%; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.86 (d, *J* = 8.4 Hz, 2H, Ar′-H-2,6), 7.25 (d, *J* = 8.4 Hz, 2H, Ar′-H-3,5), 6.92 (s, 1H, Ar-H-3), 6.56 (s, 1H, Ar-H-8), 4.08 (t, *J* = 6.4 Hz, 2H, OCH~2~), 2.44 (s, 3H, COCH~3~), 2.34 (s, 3H, COCH~3~), 2.33 (s, 3H, COCH~3~), 1.91--1.71 (m, 2H, CH~2~), 1.49--1.40 (m, 2H, CH~2~), 1.38--1.23 (m, 16H, CH~2~ × 8), 0.88 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 176.20, 168.89, 168.72, 167.82, 161.21, 155.77, 155.68, 153.16, 141.75, 130.85, 128.91, 127.46, 122.31, 111.06, 108.22, 98.71, 69.62, 31.91, 29.69, 29.65, 29.63, 29.56, 29.53, 29.33, 29.23, 28.74, 25.78, 22.67, 21.12, 20.86, 20.11, 14.10.

*7-O-Octadecanyl-5,6,4′-O-triacetylscutellarein* (**5c**) yellow solid; yield 57%; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.87 (d, *J* = 8.4 Hz, 2H, Ar′-H-2,6), 7.25 (d, *J* = 8.4 Hz, 2H, Ar′-H-3,5), 6.92 (s, 1H, Ar-H-3), 6.57 (s, 1H, Ar-H-8), 4.09 (t, *J* = 6.5 Hz, 2H, OCH~2~), 2.44 (s, 3H, COCH~3~), 2.34 (s, 3H, COCH~3~), 2.33 (s, 3H, COCH~3~), 1.91--1.74 (m, 2H, CH~2~), 1.51--1.39 (m, 2H, CH~2~), 1.26 (s, 28H, CH~2~ × 14), 0.88 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 176.22, 168.90, 168.73, 167.84, 161.24, 155.79, 155.70, 153.17, 141.78, 130.87, 128.96, 127.47, 122.33, 111.09, 108.28, 98.69, 69.63, 31.91, 29.69, 29.65, 29.57, 29.53, 29.34, 29.32, 29.23, 28.75, 25.79, 22.67, 21.13, 20.85, 20.11, 14.08.

*7-O-Oleyl-5,6,4′-O-triacetylscutellarein* (**5d**) yellow solid; yield 70%; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.86 (d, *J* = 8.8 Hz, 2H, Ar′-H-2,6), 7.24 (d, *J* = 8.8 Hz, 2H, Ar′-H-3,5), 6.91 (s, 1H, Ar-H-3), 6.56 (s, 1H, Ar-H-8), 5.43--5.30 (m, 2H, CH × 2), 4.08 (t, *J* = 6.4 Hz, 2H, OCH~2~), 2.44 (s, 3H, COCH~3~), 2.33 (s, 3H, COCH~3~), 2.33 (s, 3H, COCH~3~), 2.08--1.95 (m, 4H, CH~2~ × 2), 1.88--1.77 (m, 2H, CH~2~), 1.50--1.40 (m, 2H, CH~2~), 1.39--1.18 (m, 20H, CH~2~ × 10), 0.87 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 176.18, 168.88, 168.71, 167.80, 161.21, 155.76, 155.68, 153.17, 141.76, 130.86, 130.02, 129.74, 128.92, 127.45, 122.31, 111.08, 108.24, 98.70, 69.60, 31.89, 29.75, 29.68, 29.52, 29.44, 29.31, 29.21, 28.75, 27.23, 27.20, 25.79, 22.67, 21.11, 20.85, 20.10, 14.09.

*7-O-Hexyl-6,4′-O-diacetylscutellarein* (**6a**) yellow solid; yield 72%; ^1^H-NMR (400 MHz, CDCl~3~) δ 12.72 (s, 1H, OH), 7.89 (d, *J* = 8.8 Hz, 1H), 7.26 (d, *J* = 8.8 Hz, 2H), 6.63 (s, 1H), 6.54 (s, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 1.96--1.73 (m, 2H), 1.51--1.40 (m, 2H), 1.39--1.30 (m, 4H), 1.29--1.19 (m, 3H), 0.97--0.87 (m, 3H). ^13^C-NMR (100 MHz, CDCl~3~) δ 182.42, 168.84, 168.43, 163.30, 157.30, 154.91, 153.48, 152.60, 128.74, 127.66, 123.55, 122.41, 105.85, 105.72, 91.29, 69.44, 31.39, 29.68, 28.76, 25.44, 22.53, 21.11, 20.21, 13.95.

*7-O-Dodecyl-6,4′-O-diacetylscutellarein* (**6b**) yellow solid; yield 68%; ^1^H-NMR (400 MHz, CDCl~3~) δ 12.72 (s, 1H, OH), 7.90 (d, *J* = 8.8 Hz, 2H, Ar′-H-2,6), 7.27 (d, *J* = 8.1 Hz, 2H, Ar′-H-3,5), 6.64 (s, 1H, Ar-H-3), 6.56 (s, 1H, Ar-H-8), 4.07 (t, *J* = 6.5 Hz, 2H, OCH~2~), 2.36 (s, 3H, COCH~3~), 2.35 (s, 3H, COCH~3~), 1.96--1.70 (m, 2H, CH~2~), 1.51--1.39 (m, 2H, CH~2~), 1.39--1.14 (m, 16H, CH~2~ × 8), 0.88 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 182.44, 168.84, 168.44, 163.31, 157.31, 154.93, 153.47, 152.63, 128.78, 127.67, 123.58, 122.42, 105.88, 105.77, 91.29, 69.45, 31.91, 29.69, 29.65, 29.63, 29.57, 29.54, 29.34, 29.25, 28.81, 25.78, 22.67, 21.12, 20.23, 14.08.

*7-O-Octadecanyl-6,4′-O-diacetylscutellarein* (**6c**) yellow solid; yield 53%; ^1^H-NMR (400 MHz, CDCl~3~) δ 7.83 (d, *J* = 8.8 Hz, 2H, Ar′-H-2,6), 7.20 (d, *J* = 8.5 Hz, 2H, Ar′-H-3,5), 6.57 (s, 1H, Ar-H-3), 6.49 (s, 1H, Ar-H-8), 3.99 (t, *J* = 6.5 Hz, 2H, OCH~2~), 2.29 (s, 3H, COCH~3~), 2.27 (s, 3H, COCH~3~), 1.80--1.71 (m, 2H, CH~2~), 1.42--1.33 (m, 2H, CH~2~), 1.32--1.12 (m, 28H, CH~2~ × 14), 0.81 (t, *J* = 6.7 Hz, 6H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 182.43, 168.83, 168.42, 163.31, 157.30, 154.92, 153.48, 152.63, 130.02, 129.74, 128.77, 127.67, 122.41, 105.88, 105.76, 91.28, 69.43, 31.89, 29.77, 29.74, 29.69, 29.65, 29.52, 29.44, 29.32, 29.30, 29.22, 28.82, 27.23, 27.20, 25.79, 22.67, 21.12, 20.23, 14.08.

*7-O-Oleyl-6,4′-O-diacetylscutellarein* (**6d**) yellow solid; yield 59%; ^1^H-NMR (400 MHz, CDCl~3~) δ 12.72 (s, 1H, OH), 7.90 (d, *J* = 8.8 Hz, 2H, Ar′-H-2,6), 7.27 (d, *J* = 8.8 Hz, 2H, Ar′-H-3,5), 6.64 (s, 1H, Ar-H-3), 6.55 (s, 1H, Ar-H-8), 5.47--5.16 (m, 2H, CH × 2), 4.06 (t, *J* = 6.5 Hz, 2H, OCH~2~), 2.36 (s, 3H, COCH~3~), 2.34 (s, 3H, COCH~3~), 2.09--1.92 (m, 4H, CH~2~ × 2), 1.87--1.76 (m, 2H, CH~2~), 1.51--1.40 (m, 2H, CH~2~), 1.40--1.21 (m, 20H, CH~2~ × 10), 0.88 (t, *J* = 6.7 Hz, 3H, CH~3~). ^13^C-NMR (100 MHz, CDCl~3~) δ 182.43, 168.83, 168.42, 163.31, 157.30, 154.92, 153.48, 152.63, 130.02, 129.74, 128.77, 127.67, 122.41, 105.88, 105.76, 91.28, 69.43, 31.89, 29.77, 29.74, 29.69, 29.65, 29.52, 29.44, 29.32, 29.30, 29.22, 28.82, 27.23, 27.20, 25.79, 22.67, 21.12, 20.23, 14.08.

Cell Culture and Treatment
--------------------------

Cells were plated in 96-well plates (Jet Bio-Filtration, Guangzhou, China, 5000 cells/well in 100 μL) and grown for 24 h at 37 °C before being treated with various concentrations of the tested compounds (from 1 to 200 μM). After 48 h of incubation, CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay (MTS) solution (Promega, Madison, WI, USA) was added to each well, and the plates were further incubated for 1 h at 37 °C. The absorbance at 490 nm was measured with a Bio-Rad 680 Microplate Reader (Bio-Rad, Hercules, CA, USA). All measurements were performed in triplicate. The experiments were performed independently three times. The IC~50~ was calculated using GraphPad PRISM (GraphPad PRISM Software 6.0, San Diego, CA, USA).

4. Conclusions {#sec4-molecules-23-00310}
==============

In this study, we designed and synthesized a series of mono-aliphatic chain-modified scutellarein derivatives, and evaluated their biological activity in inhibiting cancer cell proliferation. We identified scutellarein derivatives **5a**, **5b**, **6a** and **6b** as new anti-proliferation agents for Jurkat, HCT-116 and MDA-MB-231 cells. The results showed that a proper long aliphatic chain enhanced the anti-proliferative activity of scutellarein. For our further studies, compound **6a** was selected as a promising lead in order to generate more effective anticancer agents.
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![Structures of scutellarin (**1**) and scutellarein (**2**).](molecules-23-00310-g001){#molecules-23-00310-f001}

![Reagents and conditions: a. Ac~2~O, pyridine, DMAP, reflux, 86%; b. RBr, K~2~CO~3~, DMF, 53--72%.](molecules-23-00310-sch001){#molecules-23-00310-sch001}

![HMBC spectrum of **5d**.](molecules-23-00310-g002){#molecules-23-00310-f002}

![HMBC spectrum of **6a**.](molecules-23-00310-g003){#molecules-23-00310-f003}

![Key HMBC correlations of compounds of **5d** and **6a**.](molecules-23-00310-g004){#molecules-23-00310-f004}

molecules-23-00310-t001_Table 1

###### 

In vitro antiproliferative activities of compounds.

  Compound       IC~50~ Values (μM)                   
  -------------- -------------------- --------------- ----------------
  **NaAsO~2~**   4.70 ± 0.44          31.20 ± 3.35    8.57 ± 1.13
  **1**          156.02 ± 7.21        \>200           \>200
  **2**          95.77 ± 2.56         \>200           \>200
  **3**          181.06 ± 6.21        \>200           \>200
  **4**          \>200                \>200           \>200
  **5a**         14.79 ± 2.69         22.02 ± 2.27    59.93 ± 4.46
  **5b**         22.47 ± 1.70         55.56 ± 7.21    68.54 ± 9.18
  **5c**         \>200                \>200           \>200
  **5d**         76.23 ± 9.85         184.06 ± 7.31   \>200
  **6a**         1.80 ± 0.49          11.50 ± 2.00    53.91 ± 4.04
  **6b**         19.12 ± 0.70         53.53 ± 8.25    145.01 ± 10.03
  **6c**         \>200                \>200           \>200
  **6d**         \>200                \>200           \>200
